NURIX THERAPEUTICS, INC. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
NURIX THERAPEUTICS, INC. (NRIX) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $281.54 million for the 6-month period ending 2025-05-31, per its 10-Q filed 2025-07-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2025-07-09
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-05-31 was $142.34M, a 48.30% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-02-28 was $139.20M, a 49.36% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-05-31 was $95.98M.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-02-29 was $93.20M.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $459.51M, a 42.25% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $323.04M, a 15.86% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2022 was $278.81M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2025-05-31 | $142.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $281.54M 10-Q · filed 2025-07-09 | |
| 2025-02-28 | $139.20M 10-Q · filed 2025-04-08 | ||
| 2024-11-30 | $459.51M 10-K · filed 2025-01-28 | ||
| 2024-05-31 | $95.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $189.19M 10-Q · filed 2025-07-09 | |
| 2024-02-29 | $93.20M 10-Q · filed 2025-04-08 | ||
| 2023-11-30 | $323.04M 10-K · filed 2025-01-28 | ||
| 2022-11-30 | $278.81M 10-K · filed 2025-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |